Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of Hold from Brokerages

Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) has been assigned an average recommendation of “Hold” from the twenty-three brokerages that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and six have assigned a buy rating to the company. The […]

Related Keywords

Philip Beachy ,Scott Wolchko ,Bahram Valamehr ,Leonard Zon ,Alexander Rives ,John Mendlein ,Michael Rudnicki ,Rudolf Jaenisch ,David Scadden ,Cantor Fitzgerald ,Fate Therapeutics Inc ,Ci Investments Inc ,Nasdaq ,Ef Hutton Acquisition Co ,Kessler Investment Group ,Great West Life Assurance Co ,Fate Therapeutics Company Profile ,Fate Therapeutics ,Get Rating ,Director John Mendlein ,Investment Group ,Great West Life Assurance ,Sheng Ding ,Fate Therapeutics Daily ,Nasdaq Fate ,Fate ,Medical ,Ratings ,Consensus ,